[ad_1]
The American biotechnology company “Novavax” announced that it has started the third phase of clinical trials in Great Britain for its vaccine against “Covid-19”, thus becoming the eleventh experimental vaccine in the world to reach this final stage.
The company stated that 10,000 volunteers between the ages of 18 and 84 will participate in these experiences.
The statement quoted Gregory Glenn, the company’s director of research and development, as saying that “due to the current high level of SARS-Cove-2 transmission, and given that this level will likely remain high in the UK, we are optimistic that that this A pivotal phase III clinical trial will benefit from a rapid volunteer process and provide a short-term evaluation of the efficacy of the vaccine. “
It is the eleventh vaccine in the world to enter the final stage of clinical trials, involving tens of thousands of volunteers, which are usually divided into two equal parts: half receive a placebo vaccine and the other half receive the experimental vaccine .
The most advanced Western project on the road to producing a deadly virus vaccine is the experimental vaccine developed by Oxford partner AstraZeneca, and two other vaccines developed by Pfizer and Moderna.
In parallel, similar projects are being carried out in China and Russia.
Novavax is one of six companies that received hundreds of millions of dollars in funding from the US federal government to produce a vaccine against the emerging coronavirus, and it is the fifth whose experimental vaccine enters phase three.
The company has raised more than $ 1.6 billion in public funds from the United States to produce 100 million doses of the vaccine.
[ad_2]
